Adjuvant Global Health Technology Fund DE, L.P., 10% Owner at AN2 Therapeutics, Inc. (ANTX), sold 16,517 shares at $16.07 ($266K) on 2023-09-27, disclosed to the SEC on 2023-09-29.
Scheduled sale ($266k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.07 | 134 | $2K | 0.8% |
| 2 | $16.07 | 707 | $11K | 4.3% |
| 3 | $16.11 | 1,356 | $22K | 8.2% |
| 4 | $16.11 | 7,160 | $115K | 43.4% |
| 5 | $16.11 | 7,160 | $115K | 43.4% |
| Total | $16.11 avg | 16,517 |
| $266K |
| 100% |
| Filing → |